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Abstract: Survivin is a drug target and its suppressant YM155 a drug candidate mainly investigated 
for high-risk neuroblastoma. Findings from one YM155-adapted subline of the neuroblastoma cell 
line UKF-NB-3 had suggested that increased ABCB1 (mediates YM155 efflux) levels, decreased 
SLC35F2 (mediates YM155 uptake) levels, decreased survivin levels, and TP53 mutations indicate 
YM155 resistance. Here, the investigation of 10 additional YM155-adapted UKF-NB-3 sublines only 
confirmed the roles of ABCB1 and SLC35F2. However, cellular ABCB1 and SLC35F2 levels did not 
indicate YM155 sensitivity in YM155-naïve cells, as indicated by drug response data derived from 
the Cancer Therapeutics Response Portal (CTRP) and the Genomics of Drug Sensitivity in Cancer 
(GDSC) databases. Moreover, the resistant sublines were characterized by a remarkable 
heterogeneity. Only seven sublines developed on-target resistance as indicated by resistance to 
RNAi-mediated survivin depletion. The sublines also varied in their response to other anti-cancer 
drugs. In conclusion, cancer cell populations of limited intrinsic heterogeneity can develop various 
resistance phenotypes in response to treatment. Therefore, individualized therapies will require 
monitoring of cancer cell evolution in response to treatment. Moreover, biomarkers can indicate 
resistance formation in the acquired resistance setting, even when they are not predictive in the 
intrinsic resistance setting. 
Keywords: acquired drug resistance; biomarkers; therapy monitoring; neuroblastoma; BIRC5; 
survivin; intrinsic drug resistance 
 
  
Cancers 2020, 12, 1080 2 of 17 
 
1. Introduction 
Sepantronium bromide (YM155) was introduced as an anti-cancer drug candidate that inhibits 
expression of the BIRC5 gene, which encodes the protein survivin [1]. In the meantime, YM155 has 
been suggested to exert additional and/or alternative mechanisms of anticancer actions, including 
induction of DNA damage, inhibition of NFκB signaling, induction of death receptor 5 expression, 
and/or suppression of MCL-1, XIAP, cIAP-1/2, BCL-2, BCL-XL, FLIP, EGFR, and/or mTORC [2–13]. 
A number of studies have investigated the potential of YM155 against neuroblastoma cells [14–
17]. Neuroblastoma is the most common extracranial solid childhood tumor. Treatment outcomes in 
high-risk neuroblastoma patients remain unsatisfactory. About 50% of these patients relapse and 
have a 5-year-survial rate below 10% [18–21]. We have recently shown that suppression of survivin 
expression is the main mechanism through which YM155 exerts its anti-neuroblastoma effects [16]. 
Notably, the New Drug Development Strategy (NDDS, a project of Innovative Therapies for Children 
with Cancer, the European Network for Cancer Research in Children and Adolescents, and the 
International Society of Paediatric Oncology Europe Neuroblastoma) has categorized survivin as a 
high priority drug target in neuroblastoma and YM155 as a high priority drug [22]. 
The formation of acquired resistance is a central problem in (metastasized) cancer diseases that 
need to be treated by systemic drug therapy. Although many cancers initially respond well to 
therapy, resistance formation is common, and cures are rare [23]. Hence, biomarkers that indicate 
early therapy failure are needed to adapt therapies if resistance emerges. Liquid biopsies (e.g., 
circulating tumor cells) enable the monitoring of cancer cell evolution in patients with ever more 
detail [24]. However, the translation of the resulting information into improved therapies is 
hampered by a lack of understanding of the processes underlying acquired resistance formation and, 
in turn, a lack of biomarkers. 
Most studies focus on biomarkers that indicate whether a certain cancer cell (population) is likely 
to respond to a certain treatment but not on biomarkers that indicate early that a current therapy has 
stopped working. This also applies to the previous studies that investigated the efficacy of YM155 in 
neuroblastoma [14,15,17]. However, it is known that intrinsic and acquired resistance mechanisms 
may substantially differ [25–27]. Using a single YM155-adapted neuroblastoma cell line, we identified 
increased ABCB1 (also known as P-glycoprotein or MDR1) expression, decreased SLC35F2 (solute 
carrier family 35 member F2) expression, decreased survivin expression, and loss-of-p53 function as 
potential markers of resistance formation to YM155 [16]. Given the tremendous (intra-tumor) 
heterogeneity in cancer [28], it is likely that the processes, which result in acquired resistance 
formation, are equally complex. If so, then a larger number of models of acquired resistance to a 
certain drug will be needed to adequately address the complexity of the resistance formation process.  
To test this hypothesis, we here established and characterized 10 further YM155-adapted UKF-
NB-3 neuroblastoma cell lines. Moreover, acquired resistance models may provide information that 
cannot be gained from the comparison of non-adapted cell lines with a varying resistance status. To 
investigate whether this is the case, the findings from the YM155-adapted UKF-NB-3 sublines were 
compared to data from the two large pharmacogenomics screens Genomics of Drug Sensitivity in 
Cancer (GDSC) and Cancer Therapeutic Response Portal (CTRP), which use non-adapted cancer cell 
lines [29,30], whether we can obtain information from our acquired resistance models that cannot be 
identified from traditional approaches using non-adapted cell lines. We also analyzed YM155 
response data from the two large pharmacogenomics screens Genomics of Drug Sensitivity in Cancer 
(GDSC) and Cancer Therapeutic Response Portal (CTRP) [29,30]. We found a remarkable 
heterogeneity between the individual sublines, although they all were derived from the same 
parental cell line. An increase in cellular ABCB1 levels and/or a decrease in SLC35F2 levels indicate 
resistance formation to YM155, although the ABCB1 and/or SLC35F2 levels cannot be used to infer 
YM155 sensitivity in YM155-naïve cell lines. The use of the panel of YM155-adapted cell lines further 
enabled us to show that the cellular survivin levels and the TP53 status do not reliably indicate 
resistance formation. 
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2. Results 
2.1. YM155-Adapted UKF-NB-3 Sublines Display Pronounced YM155 Resistance 
All YM155-adapted UKF-NB-3 sublines displayed pronounced YM155 resistance (Figure 1, 
Table S1). The YM155-adapted UKF-NB-3 sublines displayed between 38- and 76-fold increased 
YM155 IC50 values and between 30- and 135-fold increased IC90 values relative to UKF-NB-3 (Table 
S1). Representative photos of the morphology of the project cell lines are presented in Figure S1 and 
the doubling times in Table S1. 
 
Figure 1. YM155 concentrations that reduce the viability of UKF-NB-3 and its YM155-adapted 
sublines by 50% (IC50) or 90% (IC90) as determined by MTT assay after 120 h of incubation. The 
sublines display significantly increased YM155 resistance. Numerical values are presented in Table 
S1. * p < 0.05 relative to UKF-NB-3. 
2.2. The Cellular TP53 Status is not a Reliable Indicator of YM155 Sensitivity 
Originally, the cellular TP53 status was described to not directly influence the anticancer action 
of YM155 [31]. In agreement, the analysis of the Genomics of Drug Sensitivity in Cancer (GDSC) and 
Cancer Therapeutics Response Portal (CTRP) databases did not indicate differences in the YM155 
sensitivity between cell lines in dependence on their TP53 status (wild-type or mutant) (Figure 2). 
 
Figure 2. YM155 sensitivity in TP53 wild-type and TP53 mutant cancer cell lines based on the analysis 
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0.458; CTRP, p = 0.216) and in a neuroblastoma-specific analysis (GDSC, p = 0.922; all 12 neuroblastoma 
cell lines in the CTRP harbor wild-type TP53). The comparisons did not reveal significant differences. 
However, the activation of p53 signaling seems to be involved in the anticancer mechanism of 
action of YM155 at least in some cancer cells. We have previously shown in neuroblastoma cells that 
YM155 activates p53 signaling, that p53 activation using MDM2 inhibitors enhances the YM155 
effects, and that p53 depletion reduces cancer cell sensitivity to YM155 [15]. In addition, a YM155-
adapted UKF-NB-3 subline harbored a TP53 mutation [16]. However, all 10 YM155-adapted UKF-
NB-3 sublines that we investigated here displayed wild-type TP53 as indicated by TP53 next-
generation sequencing. The cellular p53 levels also did not differ consistently between UKF-NB-3 and 
its YM155-resistant sublines (Figure S2). The YM155-resistant UKF-NB-3 sublines remained similarly 
sensitive to the MDM2 inhibitor and p53 activator nutlin-3 as UKF-NB-3 (Table S2). Hence, our 
findings do not suggest that YM155 adaption is generally associated with a loss of p53 function in 
neuroblastoma cells. The cellular TP53 status is not a reliable indicator of YM155 sensitivity, neither 
in the intrinsic nor in the acquired resistance setting. 
2.3. Cellular Survivin Levels Do not Reliably Indicate YM155 Response 
Some studies suggested cancer cells with high survivin levels to be particularly sensitive to 
YM155 [31–33]. However, other studies failed to detect an association between the cellular survivin 
status and YM155 activity [16,34]. When we compared the YM155 sensitivity between cancer cell lines 
with high and low survivin expression, we found statistically significant differences across all cell 
lines in the GDSC and CTRP datasets but not across the neuroblastoma cell lines (Figure 3). It was 
not possible to predict whether a certain cell line was sensitive to YM155 based on the cellular 
survivin level (Figure 3).  
 
Figure 3. YM155 sensitivity in cell lines characterized by high or low survivin expression based on 
the analysis of GDSC and CTRP data, both determined across all investigated cancer types/cell lines 
(GDSC, p = 0.048; CTRP, p < 0.001) and in a neuroblastoma-specific analysis (GDSC, p = 0.425; CTRP, 
p = 0.699). Across all cell lines, high survivin expression was associated with increased YM155 
sensitivity, but the YM155 sensitivity of individual cell lines could not be predicted based on the 
survivin levels. 
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Notably, a YM155-adapted UKF-NB-3 subline had previously displayed reduced survivin levels 
relative to the parental cell line [16]. However, the analysis of the 10 additional YM155-adapted UKF-
NB-3 sublines in this study revealed that resistance acquisition to YM155 was not associated with a 
consistent change in the survivin expression patterns (Figure S3). 
2.4. Acquired YM155 Resistance Is Associated with Decreased Sensitivity to Survivin Depletion 
Our previous findings suggested that YM155 predominantly exerts its antineuroblastoma effects 
via suppression of survivin expression [16]. Seven of the 10 YM155-adapted UKF-NB-3 sublines (I, 
III, V, VII, VIII, IX, X) displayed decreased sensitivity to siRNA-mediated survivin depletion, 
indicating that they developed on-target resistance. However, two sublines were similarly sensitive 
as parental UKF-NB-3 cells (II, VI), and one subline (IV) was more sensitive to survivin depletion 
(Figure 4, Figure S4). This shows that the YM155 resistance mechanisms differ between the individual 
UKF-NB-3 sublines. Notably, the viability of all sublines is still affected by survivin depletion, which 
shows that they have retained some level of survivin dependence. 
 
Figure 4. Effects of siRNA-mediated BIRC5/survivin depletion on the viability of UKF-NB-3 and its 
YM155-adapted sublines. Western blots confirm reduced survivin levels 48 h post-transfection. 
Viability of cells transduced with siRNA directed against BIRC5/survivin or non-targeting siRNA was 
determined relative to untreated control cells 168 h post transfection by MTT assay. The cell lines 
displayed varying levels of sensitivity to survivin depletion. * p < 0.05 relative to untreated cells. 
Uncropped blots are shown in Figure S4. 
  
Cancers 2020, 12, 1080 6 of 17 
 
2.5. Relevance of Cellular ABCB1 and SLC35F2 Levels in the Context of YM155 Resistance 
Increased cellular ABCB1 (mediates YM155 efflux) levels and decreased SLC35F2 (mediates 
cellular YM155 uptake) levels have previously been identified as important YM155 resistance 
mechanisms [14,16,17,35]. To further investigate the relationship between ABCB1 and SLC35F2 levels 
and YM155 sensitivity, we compared the YM155 sensitivity in cell lines that displayed low or high 
expression of the respective genes using GDSC and CTRP data. In agreement with previous data, 
high ABCB1 expression (Figure 5) and low SLC35F2 expression (Figure 6) were associated with 
reduced YM155 sensitivity. When we used transcriptomics data from the GDSC and CTRP to 
correlate the expression of all genes with YM155 sensitivity, ABCB1 ranked as the gene whose 
expression was most strongly correlated to the YM155 AUC (area under the curve, unit used to 
quantify the drug response) (Table 1) in the GDSC and CTRP. SLC35F2 expression was most strongly 
inversely correlated to the YM155 AUC (Table 2) in both data sets. There were no further overlaps 
among the top 10 genes between the two databases (Tables 1 and 2). However, the YM155 sensitivity 
of a certain cell line could not be reliably predicted based on the cellular ABCB1 and/or SLC35F2 
levels (Figures 5 and 6). 
 
Figure 5. YM155 sensitivity in cancer cell lines characterized by high or low ABCB1 expression based 
on the analysis of GDSC and CTRP data, both determined across all investigated cancer types/cell 
lines (GDSC, p < 0.001; CTRP, p < 0.001) and in a neuroblastoma-specific analysis (GDSC, p = 0.006; 
CTRP, p = 0.04). High ABCB1 expression was associated with decreased YM155 sensitivity, but the 
YM155 sensitivity of individual cell lines could not be predicted based on the ABCB1 levels. 
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Figure 6. YM155 sensitivity in cancer cell lines characterized by high or low SLC35F2 expression based 
on the analysis of GDSC and CTRP data, both determined across all investigated cancer types/cell 
lines (GDSC, p < 0.001; CTRP, p < 0.001) and in a neuroblastoma-specific analysis (GDSC, p = 0.033; 
CTRP, p = 0.310). High SLC35F2 expression was associated with increased YM155 sensitivity, but the 
YM155 sensitivity of individual cell lines could not be predicted based on their SLC35F2 levels. 
Table 1. Top 10 genes whose expression is most strongly correlated with the YM155 AUC in the 
Genomics of Drug Sensitivity in Cancer (GDSC) database and the Cancer Therapeutics Response 
Portal (CTRP) as indicated by the Pearson correlation coefficient. 
GDSC   CTRP   
Gene Correlation Coefficient FDR 1 Gene Correlation Coefficient FDR 
ABCB1 0.3792069 2.82E-06 ABCB1 0.3624858 2.70E-06 
FABP1 0.2972293 5.64E-06 CST3 0.3603422 5.39E-06 
CDX2 0.2927057 8.46E-06 AKR1C3 0.3503176 8.09E-06 
DDC 0.2922995 1.13E-05 EPS8 0.3453892 1.08E-05 
CDH17 0.2652645 1.41E-05 ABHD2 0.3309384 1.35E-05 
ANKS4B 0.2637047 1.97E-05 S100A6 0.3229691 1.62E-05 
MYO1A 0.2626518 2.26E-05 ATP1B1 0.3111308 1.89E-05 
PHGR1 0.2609317 2.54E-05 CD63 0.310712 2.16E-05 
A1CF 0.252912 2.82E-05 AKR1C1 0.3073306 2.43E-05 
GUCY2C 0.2513048 3.10E-05 ACVR1 0.30124 9.44E-05 
1 false discovery rate. 
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Table 2. Top 10 genes whose expression is most strongly inversely correlated with the YM155 AUC 
in the Genomics of Drug Sensitivity in Cancer (GDSC) database and the Cancer Therapeutics 
Response Portal (CTRP) as indicated by the Pearson correlation coefficient. 








SLC35F2 −0.2643809 1.69E-05 SLC35F2 −0.3868041 9.17E-05 
ALKBH8 −0.2042557 0.000121 CD19 −0.349156 8.90E-05 
CWF19L2 −0.1926243 0.000180 CD79B −0.346035 8.63E-05 
RCSD1 −0.1855956 0.000226 SPIB −0.341887 8.36E-05 
P2RY8 −0.1834937 0.000257 SNX22 −0.338893 8.09E-05 
RGS19 −0.1831031 0.000259 TCL1A −0.338393 7.82E-05 
FLI1 −0.1825892 0.000268 LOC100130458 −0.337940 7.55E-05 
VAV1 −0.1819569 0.000273 BLK −0.330471 7.28E-05 
ATM −0.1816322 0.000276 CD79A −0.324465 7.01E-05 
ARHGAP19 −0.1813872 0.000282 VPREB3 −0.322878 6.74E-05 
1 false discovery rate. 
All YM155-adapted UKF-NB-3 sublines displayed increased ABCB1 levels relative to UKF-NB-
3 (Figure 7, Figure S5). Acquired YM155 resistance was also generally associated with decreased 
SLC35F2 levels, in particular in the sublines I, IV, VI, and X (Figure 7, Figure S5). This indicates that 
increased ABCB1 levels and decreased SLC35F2 levels have potential as biomarkers, indicating 
YM155 resistance formation in response to YM155-based therapies, although cellular ABCB1 and 
SLC35F2 levels do not enable the prediction of YM155 sensitivity in YM155-naïve cells. 
 
Figure 7. Representative Western blots indicating cellular levels of ABCB1 and SLC35F2 in UKF-NB-
3 and YM155-adapted UKF-NB-3 sublines. YM155-adapted sublines are typically characterized by 
increased ABCB1 levels and decreased SLC35F2 levels. Uncropped blots are shown in Figure S5. 
2.6. YM155-Adapted UKF-NB-3 Cells Remain Sensitive to DNA Damage Caused by Irradiation and 
Cytotoxic Drugs 
YM155 has been proposed to exert its anticancer effects via the induction of DNA damage in 
some experimental systems [3,5,35,36]. To study whether the acquisition of YM155 resistance was 
associated with a generally increased resistance to DNA damage, UKF-NB-3 and its YM155-adapted 
UKF-NB-3 sublines were irradiated at a dose range of one to five Gy. None of the YM155-adapted 
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(Figure 8). Moreover, none of the YM155-resistant UKF-NB-3 sublines displayed reduced sensitivity 
to cisplatin (causes DNA crosslinks) or topotecan (topoisomerase I inhibitor), which cause DNA 
damage by different mechanisms (Figure 8, Table S2). There was also no coherent increase in 
resistance to the nucleoside analogue gemcitabine (Figure 8, Table S2). These data do not suggest that 
the activity of YM155 against UKF-NB-3 cells would predominantly depend on DNA damage 
induction. 
 
Figure 8. Sensitivity of UKF-NB-3 and its YM155-adapted sublines to irradiation and DNA-damaging 
drugs. The radiation response was determined 72 h after irradiation with 1, 3, or 5Gy by MTT assay. 
Drug concentrations that reduce cell viability by 50% (IC50) were determined by MTT assay after 120 
h of incubation. The YM155-adapted sublines did not display increased resistance to DNA damage 
induced by radiation or the drugs cisplatin, gemcitabine, or topotecan. * p < 0.05 relative to UKF-NB-
3. 
2.7. Heterogeneity Among YM155-Adapted UKF-NB-3 Sublines 
While the YM155-adapted UKF-NB-3 sublines displayed limited heterogeneity in response to 
treatment with cisplatin and topotecan, remarkable differences in the gemcitabine IC50s were detected 
(Figure 8, Table S2). The fold difference between the YM155-adapted subline with the lowest 
gemcitabine IC50 (V, 0.12 ng/mL) and the subline with the highest IC50 (VIII, 0.65 ng/mL) was 5.4-fold. 
This heterogeneity is in agreement with the up to 29-fold difference observed in the cell viability in 
response to BIRC5/survivin depletion between the most sensitive (IV) and the most resistant (VII) 
subline (Figure 4). Resistance profiles to the destabilizing tubulin-binding agent vincristine also 
revealed a substantial heterogeneity between the YM155-resistant UKF-NB-3 sublines (Figure 9, 
Table S2), resulting in a fold difference of 127 between subline VI (vincristine IC50: 714 ng/mL) and 
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Figure 9. Vincristine concentrations that reduce cell viability by 50% (IC50) were determined by MTT 
assay after 120 h of incubation. YM155-adapted sublines consistently displayed decreased vincristine 
sensitivity relative to UKF-NB-3. The vincristine IC50 values varied considerably. * p < 0.05 relative to 
UKF-NB-3. 
3. Discussion 
In a previous study, a YM155-adapted subline of the neuroblastoma cell line UKF-NB-3 was 
characterized by increased cellular ABCB1 levels, decreased SLC35F2 and survivin levels, and a TP53 
mutation [16]. Here, we systematically investigated the relevance of cellular ABCB1, SLC35F2, and 
survivin levels as well as the TP53 status as potential biomarkers of YM155 resistance formation in 
the intrinsic resistance setting, using data derived from the GDSC and CTRP databases [29,30], and 
in the acquired resistance setting, using an additional set of 10 YM155-adapted UKF-NB-3 sublines, 
which were established in independent experiments. 
Increased ABCB1 expression (mediates YM155 efflux) and decreased SLC35F2 expression 
(mediates cellular YM155 uptake) were identified as YM155 resistance mechanisms in panels of 
YM155-naïve cell lines that displayed varying levels of these proteins and in functional studies 
[14,16,17,37], which was further supported by our analysis of GDSC and CTRP data [29,30]. Despite 
their roles in determining YM155 resistance, however, cellular ABCB1 or SLC35F2 levels did not 
enable the prediction of whether an individual cell line would be sensitive to YM155 or not. The 
YM155-adapted UKF-NB-3 cell lines generally displayed elevated cellular ABCB1 levels and reduced 
SLC35F2 levels relative to UKF-NB-3. Hence, an increase in the cellular ABCB1 levels and/or a 
decrease in the SLC35F2 levels have potential as biomarkers that indicate resistance formation, even 
though the respective cellular levels do not reliably predict the YM155 response in YM155-naïve cells. 
Initially, the TP53 status was reported not to influence the anticancer effects of YM155 [31], 
which was further supported by our analysis of GDSC and CTRP data. In neuroblastoma cells, 
however, YM155 induced p53 signaling, p53 depletion reduced YM155 sensitivity, and a YM155-
adapted UKF-NB-3 subline harbored a TP53 mutation [16]. Here, all 10 YM155-adapted UKF-NB-3 
sublines retained wild-type TP53. Thus, the role of p53 seems to depend on the individual cellular 
context. Neither the cellular TP53 status nor the formation of TP53 mutations can currently be 
considered as valid biomarkers for YM155 therapies. 
The relevance of cellular survivin levels for cancer cell sensitivity to YM155 is not clear [16,31–
35]. Our analysis of GDSC and CTRP data indicated that high survivin (BIRC5) expression was 
associated with increased YM155 sensitivity. However, it was not possible to infer the YM155 
sensitivity of a particular cell line based on its survivin status. Reasons for this may include that 
survivin is not in all cell lines the major therapeutic target of YM155 as it is in neuroblastoma cells [1–
12,16,36] and/or that off-target resistance mechanisms, such as ABCB1 and SLC35F2 expression, may 
affect YM155 efficacy independently of the survivin status [14,16,17,35]. 
The YM155-adapted UKF-NB-3 sublines displayed various survivin levels, demonstrating that 
resistance formation to YM155 is also not associated with a consistent change in cellular survivin 
levels. Seven of the YM155-adapted cell lines displayed on-target resistance as indicated by reduced 
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confirming that survivin is a target of YM155 in neuroblastoma cells. However, cellular survivin 
levels do not represent a reliable biomarker of resistance formation to YM155. 
While YM155 was described to act via the induction of DNA damage in some cancer types 
[3,5,35,36], our previous results did not indicate a causative role of DNA damage induction in the 
anticancer effects of YM155 against neuroblastoma cells [16]. YM155 resistance formation in the 
YM155-adapted neuroblastoma cell lines was also not associated with generally decreased sensitivity 
to radiation or DNA damage caused by cisplatin (causes DNA crosslinks), gemcitabine (nucleoside 
analogue), or topotecan (topoisomerase I inhibitor). This indicates that YM155 resistance formation 
in neuroblastoma cells is not generally associated with an increased resistance to DNA damage 
induction. 
In this study, the use of multiple models of acquired resistance enabled insights that could not 
be gained from just one drug-adapted subline. The previous investigation of one YM155-resistant 
UKF-NB-3 subline had suggested that changes in the cellular TP53 status and survivin levels indicate 
resistance formation [16], which was not confirmed in our current panel of 10 YM155-adapted UKF-
NB-3 sublines. Moreover, the use of multiple sublines provided a novel glimpse into the significant 
heterogeneity of the resistance formation process, even though all resistant sublines were derived 
from the same parental cell line. Only 7 of the 10 sublines developed on-target resistance mechanisms 
as indicated by reduced sensitivity to survivin depletion. The sublines also showed substantial 
variation in their sensitivity to irradiation (up to 7-fold difference at 5Gy), gemcitabine (up to 5-fold), 
and vincristine (up to 127-fold). Notably, a much higher heterogeneity would be expected in the 
clinical situation, in which tumors are already characterized by much higher heterogeneity than 
cancer cell lines and in which combination therapies are common. 
4. Materials and Methods  
4.1. Cells 
The MYCN-amplified neuroblastoma cell line UKF-NB-3 was established from a bone marrow 
metastasis of a stage IV neuroblastoma patient [38]. Ten YM155-resistant UKF-NB-3 sublines were 
derived from the resistant cancer cell line (RCCL) collection (https://research.kent.ac.uk/industrial-
biotechnology-centre/the-resistant-cancer-cell-line-rccl-collection/). They were established by 
adaptation of UKF-NB-3 cells (passage 87) to growth in the presence of YM155 20nM by previously 
described methods [39] and designated as UKF-NB-3rYM15520nMI to UKF-NB-3rYM15520nMX. All cells 
were propagated in IMDM supplemented with 10 % FBS, 100 IU/mL penicillin, and 100 µg/mL 
streptomycin at 37 °C. Cells were routinely tested for mycoplasma contamination (PlasmoTest™, 
Mycoplasma Detection kit, InvivoGen, Toulouse, France) and authenticated by short tandem repeat 
profiling. 
To determine doubling times, 2 × 104 cells per well were plated into 6-well plates, incubated at 
37 °C and 5% CO2, and counted after 1, 2, 3, 5, and 7 days using a Neubauer chamber. Doubling times 
were then calculated using http://www.doubling-time.com/compute.php, which uses the equation: 
Doubling time = duration × log(2)/log(final cell number)−log(initial cell number). 
4.2. Viability Assay 
Cell viability was tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) dye reduction assay after 120 h of incubation modified as described previously [39]. Cells (2 × 
104/100 µL per well in 96-well plates) were incubated in the presence or absence of drug for 120 h. 
Then, 25 µL of MTT solution (2 mg/mL (w/v) in PBS) were added per well, and the plates were 
incubated at 37 °C for an additional 4 h. After this, the cells were lysed using 100 µL of a buffer 
containing 20% (w/v) sodium dodecylsulfate and 50% (v/v) N,N-dimethylformamide with the pH 
adjusted to 4.7 at 37 °C for 4 h. Absorbance was determined at 570 nm for each well using a 96-well 
multiscanner. After subtraction of the background absorption, the results were expressed as the 
percentage viability relative to control cultures that received no drug. Drug concentrations that 
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inhibited cell viability by 50% (IC50) or 90% (IC90) were determined using CalcuSyn (Biosoft, 
Cambridge, UK). 
4.3. TP53 Next-Generation Sequencing 
TP53 next-generation sequencing was performed as previously described [16]. All coding exonic 
and flanking intronic regions of the human TP53 gene were amplified from genomic DNA with 
Platinum™ Taq DNA polymerase (Life Technologies) by multiplex PCR using two primer pools with 
12 non-overlapping primer pairs each, yielding approximately 180 bp amplicons. Each sample was 
tagged with a unique 8-nucleotide barcode combination using 12 differently barcoded forward and 
eight differently barcoded reverse primer pools. Barcoded PCR products from up to 96 samples were 
pooled, purified, and an indexed sequencing library was prepared using the NEBNext® ChIP-Seq 
Library Prep Master Mix Set for Illumina in combination with NEBNext® Multiplex Oligos for 
Illumina (New England Biolabs). The quality of sequencing libraries was verified on a Bioanalyzer 
DNA High Sensitivity chip (Agilent) and quantified by digital PCR. 2 × 250 bp paired-end sequencing 
was carried out on an Illumina MiSeq (Illumina) according to the manufacturer’s recommendations 
at a mean coverage of 300×. 
Read pairs were demultiplexed according to the forward and reverse primers and subsequently 
aligned using the Burrows-Wheeler Aligner against the Homo sapiens Ensembl reference (rev. 79). 
Overlapping mate pairs where combined and trimmed to the amplified region. Coverage for each 
amplicon was calculated via SAMtools (v1.1) [40]. To identify putative mutations, variant calling was 
performed using SAMtools in combination with VarScan2 (v2.3.9) [41]. Initially, SAMtools was used 
to create pileups with a base quality filter of 15. Duplicates, orphan reads, unmapped, and secondary 
reads were excluded. Subsequently, Varscan2 was applied to screen for SNVs and InDels separately, 
using a low-stringency setting with minimal variant frequency of 0.1, a minimum coverage of 20, and 
a minimum of 10 supporting reads per variant to account for cellular and clonal heterogeneity. 
Minimum average quality was set to 20 and a strand filter was applied to minimize miscalls due to 
poor sequencing quality or amplification bias. The resulting list of putative variants was compared 
against the IARC TP53 (R17) database to check for known p53 cancer mutations. 
4.4. Western Blot 
Cells were lysed using Triton-X-100 sample buffer, and proteins were separated by SDS-PAGE. 
Detection occurred by using specific antibodies against β-actin (1:5000 dilution, Biovision through 
BioCat GmbH, Heidelberg Germany; secondary antibody: IRDye® 800CW Goat anti-Mouse IgG, 
dilution 1:25,000, Li-Cor Biosciences, Lincoln, NE, USA), SLC35F2 (1:200, Santa Cruz Biotechnology, 
Dallas, TX, USA; secondary antibody: IRDye® 800CW Goat anti-Mouse IgG, dilution 1:25,000, Li-Cor 
Biosciences, Lincoln, NE, USA), GAPDH (1:4000, Trevigen via Bio-Techne GmbH, Wiesbaden, 
Germany; secondary antibody: IRDye® 800CW Goat anti-Rabbit IgG, dilution 1:25,000, Li-Cor 
Biosciences), ABCB1 (1:1,000, Cell Signaling via New England Biolabs, Frankfurt, Germany; 
secondary antibody: IRDye® 800CW Goat anti-Rabbit IgG, dilution 1:25,000, Li-Cor Biosciences), p53 
(1:1000, Enzo Life Sciences, Lörrach, Germany; secondary antibody: IRDye® 800CW Goat anti-Mouse 
IgG, dilution 1:25,000, Li-Cor Biosciences), and survivin (1:500, R&D Systems, Minneapolis, MN, 
USA; secondary antibody: IRDye® 800CW Goat anti-Rabbit IgG, dilution 1:25,000, Li-Cor 
Biosciences). Protein bands were visualized by laser-induced fluorescence using infrared scanner for 
protein quantification (Odyssey, Li-Cor Biosciences) and Image Studio Ver. 5.2 software (Li-Cor 
Biosciences) for densitometric analyses. 
4.5. RNA Interference Experiments 
Transient depletion of BIRC5/survivin was achieved using synthetic siRNA oligonucleotides 
(ON-TARGETplus SMARTpool) from Dharmacon (Lafayette, CO, USA). Non-targeting siRNA (ON-
TARGETplus SMARTpool) was used as negative control. Cells were transfected by electroporation 
using the NEON Transfection System (Invitrogen, Darmstadt; Germany) according to the 
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manufacturer protocol. Cells were grown to 60–80% confluence, trypsinised, and 1.2 × 106 cells were 
re-suspended in 200 µL of resuspension buffer R including 2.5 µM siRNA. The electroporation was 
performed using two 20 ms pulses of 1400 V. Subsequently, the cells were transferred into cell culture 
plates or flasks, containing pre-warmed cell culture medium. During the set-up of the experiments, 
the SMARTpool was compared to two individual siRNAs (target sequences: 
GCAAAGGAAACCAACAAUA, GGAAAGGAGAUCAACAUUU) (Figure S6). 
4.6. Irradiation Procedure 
In 96-well cell culture plates, 104 cells per well were irradiated at room temperature (Greiner, 
Bio-ONE GmbH, Frickenhausen, Germany) with single doses of X-rays ranging from 1 to 5 Gy using 
a linear accelerator (SL 75/5, Elekta, Crawley, UK) with 6 MeV photons/100 cm focus–surface distance 
with a dose rate of 4.0 Gy/min. Sham-irradiated cultures were kept at room temperature in the X-ray 
control room while the other samples were irradiated. 
4.7. Analysis of Data Derived from Large Pharmacogenomic Studies 
All data (including drug response area under curve (AUC) data for YM-155-treated cancer cell 
lines, basal gene-expression for ABCB1, BIRC5 (the gene that encodes survivin), and SLC35F2, and 
genomic alterations of p53) in this study were obtained from two online resources: Version 2 of the 
Cancer Therapeutics Response Portal (CTRP v2) data [29,42] were obtained from the Cancer Target 
Discovery and Development (CTD2) data portal (ocg.cancer.gov/programs/ctd2/data-portal). The 
Genomics of Drug Sensitivity in Cancer (GDSC) data were obtained from www.cancerrxgene.org 
[43,44]. 
The CTRP contains ABCB1, BIRC5, and SLC35F2 expression data for 823 cell lines and YM-155 
AUC data for 715 cell lines. For 703 cell lines (including 12 neuroblastoma cell lines), gene expression 
data and YM155 AUC values were available. Whole exome sequencing (WES) data was available for 
546 of the cell lines for which YM-155 sensitivity data was also available (including 11 neuroblastoma 
cell lines). 
The GDSC contains ABCB1, BIRC5, and SLC35F2 expression data for 1019 cell lines and YM155 
AUC data for 945 cell lines. Expression data and WES data were available for all 945 cell lines with 
YM-155 sensitivity data (including 30 neuroblastoma cell lines). 
Data processing was performed using Perl version 5.26.0, and R statistical packages version 
3.3.2. Cell lines were determined to display either high or low expression for each gene using the 
median gene expression as a threshold (i.e., low expression < = median expression, high expression > 
median expression). Box plots indicating the YM-155 sensitivity in cell lines that display low or high 
expression of a certain gene or wild-type or mutant TP53 were produced using the ggplot2 package 
[45] in R. 
Statistical tests were carried out in R and included Wilcoxon rank-sum test [46] and Pearson’s 
correlation [47]. Correction for multiple comparisons was performed using the Benjamini–Hochberg 
procedure [37]. 
4.8. Statistics 
Results are expressed as mean ± S.D. of at least three experiments. Comparisons between the 
means of two sample groups were performed using Student’s t-test. The means of three or more 
sample groups were compared by one-way ANOVA followed by the Student–Newman–Keuls test. 
P values lower than 0.05 were considered to be significant. 
5. Conclusions 
Our data revealed a high phenotypic heterogeneity among a panel of 10 YM155-resistant 
sublines of the neuroblastoma cell line UKF-NB-3. This heterogeneity is of conceptual importance, 
because it shows that even a defined cancer cell population of limited intrinsic heterogeneity can 
develop various resistance mechanisms and phenotypes in response to treatment. From a clinical 
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perspective, this means that the close monitoring of cancer cell evolution in response to therapy will 
have to become an essential part of the design of individualized therapies. Notably, such insights can 
only be gained from preclinical model systems, such as drug-adapted cancer cell lines, which enable 
the repeated adaptation of a given cancer cell population to the same treatment but not from clinical 
material as every patient can only be treated once. 
Our findings also demonstrate that biomarkers can indicate resistance formation, even when 
they do not enable the prediction of drug sensitivity in therapy-naïve cancer cells. Hence, the use of 
biomarkers differs between the intrinsic and the acquired resistance setting, and pre-clinical models 
of acquired drug resistance are needed for the identification of such biomarkers that herald resistance 
development. 
Supplementary Materials: The following are available online at www.mdpi.com/2072-6694/12/5/1080/s1, Figure 
S1: Representative photos of the project cell lines, Figure S2: Representative Western blots indicating cellular 
levels of p53 in UKF-NB-3 and YM155-adapted UKF-NB-3 sub-lines, Figure S3: Representative Western blots 
indicating cellular levels of survivin in UKF-NB-3 and YM155-adapted UKF-NB-3 sub-lines, Figure S4: 
Representative Western blots indicating cellular levels of survivin in UKF-NB-3 and its YM155-adapted UKF-
NB-3 sub-lines 48h after transfection with non-targeting siRNA or siRNA directed against BIRC5/ survivin, 
Figure S5: Representative Western blots indicating cellular levels of ABCB1 and SLC35F2 in UKF-NB-3 and 
YM155-adapted UKF-NB-3 sub-lines, Figure S6: Effects of different siRNAs in UKF-NB-3 cells, Table S1: YM155 
concentrations (nM) that reduce the viability of UKF-NB-3 or YM155-adapted UKF-NB-3 sub-lines by 50% (IC50) 
or 90% (IC90), Table S2: Drug concentrations that reduce the viability of UKF-NB-3 or YM155-adapted UKF-NB-
3 sub-lines by 50% (IC50). 
Author Contributions: Conceptualization, M.Mi. and J.C.jr.; methodology, M.Mi., M.N.W., T.S., Fr.R., J.C.Jr.; 
formal analysis, all authors; investigation, all authors; resources, M.M.., M.N.W., T.S., Fr.R., J.C.Jr.; data curation, 
all authors; writing—original draft preparation, M.Mi.; writing—review and editing, all authors; supervision, 
M.Mi., M.N.W., T.S., Fr.R., J.C.Jr.; project administration, M.M., J.C.jr.; funding acquisition, J.C.jr. All authors 
have read and agreed to the published version of the manuscript.  
Funding: This research was funded by the Hilfe für krebskranke Kinder Frankfurt e.V. and the Frankfurter 
Stiftung für krebskranke Kinder. The APC was funded by institutional membership of the Goethe-University. 
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the 
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to 
publish the results. 
References 
1. Nakahara, T.; Kita, A.; Yamanaka, K.; Mori, M.; Amino, N.; Takeuchi, M.; Tominaga, F.; Hatakeyama, S.; 
Kinoyama, I.; Matsuhisa, A.; et al. YM155, a novel small-molecule survivin suppressant, induces regression 
of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007, 67, 8014–8021. 
2. Tang, H.; Shao, H.; Yu, C.; Hou, J. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor 
activities with ABT-263. Biochem. Pharmacol. 2011, 82, 1066–1072. 
3. Glaros, T.G.; Stockwin, L.H.; Mullendore, M.E.; Smith, B.; Morrison, B.L.; Newton, D.L. The “survivin 
suppressants” NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother. Pharmacol. 2012, 
70, 207–212. 
4. Na, Y.S.; Yang, S.J.; Kim, S.M.; Jung, K.A.; Moon, J.H.; Shin, J.S.; Yoon, D.H.; Hong, Y.S.; Ryu, M.H.; Lee, 
J.L.; et al. YM155 induces EGFR suppression in pancreatic cancer cells. PLoS ONE 2012, 7, e38625. 
5. Rauch, A.; Hennig, D.; Schäfer, C.; Wirth, M.; Marx, C.; Heinzel, T.; Schneider, G.; Krämer, O.H. Survivin 
and YM155: How faithful is the liaison? Biochim. Biophys. Acta 2014, 1845, 202–220. 
6. Cheng, S.M.; Chang, Y.C.; Liu, C.Y.; Lee, J.Y.; Chan, H.H.; Kuo, C.W.; Lin, K.Y.; Tsai, S.L.; Chen, S.H.; Li, 
C.F.; et al. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-
dependent DNA damage in breast cancer cells. Br. J. Pharmacol. 2015, 172, 214–234. 
7. de Necochea-Campion, R.; Diaz Osterman, C.J.; Hsu, H.W.; Fan, J.; Mirshahidi, S.; Wall, N.R.; Chen, C.S. 
AML sensitivity to YM155 is modulated through AKT and Mcl-1. Cancer Lett. 2015, 366, 44–51. 
8. Jung, S.A.; Park, Y.M.; Hong, S.W.; Moon, J.H.; Shin, J.S.; Lee, H.R.; Ha, S.H.; Lee, D.H.; Kim, J.H.; Kim, 
S.M.; et al. Cellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in 
human gastric cancer cells. J. Biol. Chem. 2015, 290, 9974–9985. 
Cancers 2020, 12, 1080 15 of 17 
 
9. Pennati, M.; Sbarra, S.; De Cesare, M.; Lopergolo, A.; Locatelli, S.L.; Campi, E.; Daidone, M.G.; Carlo-Stella, 
C.; Gianni, A.M.; Zaffaroni, N. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL 
through p38 MAPK- and CHOP-mediated DR5 upregulation. Int. J. Cancer 2015, 136, 299–309. 
10. Zhao, X.; Puszyk, W.M.; Lu, Z.; Ostrov, D.A.; George, T.J.; Robertson, K.D.; Liu, C. Small molecule inhibitor 
YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic 
carcinoma. Mol. Cancer Ther. 2015, 14, 80–89. 
11. Ho, S.H.; Ali, A.; Chin, T.M.; Go, M.L. Dioxonaphthoimidazoliums AB1 and YM155 disrupt 
phosphorylation of p50 in the NF-κB pathway. Oncotarget 2016, 7, 11625–11636. 
12. Kojima, Y.; Hayakawa, F.; Morishita, T.; Sugimoto, K.; Minamikawa, Y.; Iwase, M.; Yamamoto, H.; Hirano, 
D.; Imoto, N.; Shimada, K.; et al. YM155 induces apoptosis through proteasome-dependent degradation of 
MCL-1 in primary effusion lymphoma. Pharmacol. Res. 2017, 120, 242–251. 
13. Danielpour, D.; Gao, Z.; Zmina, P.M.; Shankar, E.; Shultes, B.C.; Jobava, R.; Welford, S.M.; Hatzoglou, M. 
Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve 
Suppression of mTORC1 by AMPK. Sci. Rep. 2019, 9, 11541. 
14. Lamers, F.; Schild, L.; Koster, J.; Versteeg, R.; Caron, H.N.; Molenaar, J.J. Targeted BIRC5 silencing using 
YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur. J. Cancer. 2012, 48, 763–
771. 
15. Liang, H.; Zhang, L.; Xu, R.; Ju, X.L. Silencing of survivin using YM155 induces apoptosis and 
chemosensitization in neuroblastomas cells. Eur. Rev. Med. Pharmacol. Sci. 2013, 17, 2909–2915. 
16. Voges, Y.; Michaelis, M.; Rothweiler, F.; Schaller, T.; Schneider, C.; Politt, K.; Mernberger, M.; Nist, A.; 
Stiewe, T.; Wass, M.N.; et al. Effects of YM155 on survivin levels and viability in neuroblastoma cells with 
acquired drug resistance. Cell Death Dis. 2016, 7, e2410. 
17. Radic-Sarikas, B.; Halasz, M.; Huber, K.V.M.; Winter, G.E.; Tsafou, K.P.; Papamarkou, T.; Brunak, S.; Kolch, 
W.; Superti-Furga, G. Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the 
ABCB1 efflux transporter. Sci. Rep. 2017, 7, 3091. 
18. Pinto, N.R.; Applebaum, M.A.; Volchenboum, S.L.; Matthay, K.K.; London, W.B.; Ambros, P.F.; 
Nakagawara, A.; Berthold, F.; Schleiermacher, G.; Park, J.R.; et al. Advances in Risk Classification and 
Treatment Strategies for Neuroblastoma. J. Clin. Oncol. 2015, 33, 3008–3017. 
19. Bagatell, R.; Cohn, S.L. Genetic discoveries and treatment advances in neuroblastoma. Curr. Opin. Pediatr. 
2016, 28, 19–25. 
20. Speleman, F.; Park, J.R.; Henderson, T.O. Neuroblastoma: A Tough Nut to Crack. Am. Soc. Clin. Oncol. Educ. 
Book 2016, 35, e548–557. 
21. PDQ Pediatric Treatment Editorial Board. Neuroblastoma Treatment (PDQ®): Health Professional Version. 
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 6 February 
2002–2020. Available online: https://www.ncbi.nlm.nih.gov/books/NBK65747/ (accessed on 13 February 
2020). 
22. Moreno, L.; Caron, H.; Geoerger, B.; Eggert, A.; Schleiermacher, G.; Brock, P.; Valteau-Couanet, D.; Chesler, 
L.; Schulte, J.H.; De Preter, K.; et al. Accelerating Drug Development for Neuroblastoma—New Drug 
Development Strategy: An Innovative Therapies for Children with Cancer, European Network for Cancer 
Research in Children and Adolescents and International Society of Paediatric Oncology Europe 
Neuroblastoma Project. Expert. Opin. Drug Discov. 2017, 12, 801–811. 
23. Holohan, C.; Van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G. Cancer drug resistance: An evolving 
paradigm. Nat. Rev. Cancer 2013, 13, 714–726. 
24. Perakis, S.; Speicher, M.R. Emerging concepts in liquid biopsies. BMC Med. 2017, 15, 75. 
25. Miklos, W.; Pelivan, K.; Kowol, C.R.; Pirker, C.; Dornetshuber-Fleiss, R.; Spitzwieser, M.; Englinger, B.; van 
Schoonhoven, S.; Cichna-Markl, M.; Koellensperger, G.; et al. Triapine-mediated ABCB1 induction via PKC 
induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. Cancer 
Lett. 2015, 361, 112–120. 
26. Hata, A.N.; Niederst, M.J.; Archibald, H.L.; Gomez-Caraballo, M.; Siddiqui, F.M.; Mulvey, H.E.; Maruvka, 
Y.E.; Ji, F.; Bhang, H.E.; Krishnamurthy Radhakrishna, V.; et al. Tumor cells can follow distinct evolutionary 
paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 2016, 22, 262–269. 
  
Cancers 2020, 12, 1080 16 of 17 
 
27. Carter, L.; Rothwell, D.G.; Mesquita, B.; Smowton, C.; Leong, H.S.; Fernandez-Gutierrez, F.; Li, Y.; Burt, 
D.J.; Antonello, J.; Morrow, C.J.; et al. Molecular analysis of circulating tumor cells identifies distinct copy-
number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat. Med. 
2017, 23, 114–119. 
28. Lipinski, K.A.; Barber, L.J.; Davies, M.N.; Ashenden, M.; Sottoriva, A.; Gerlinger, M. Cancer Evolution and 
the Limits of Predictability in Precision Cancer Medicine. Trends Cancer 2016, 2, 49–63. 
29. Basu, A.; Bodycombe, N.E.; Cheah, J.H.; Price, E.V.; Liu, K.; Schaefer, G.I.; Ebright, R.Y.; Stewart, M.L.; Ito, 
D.; Wang, S.; et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by 
small molecules. Cell 2013, 154, 1151–1161. 
30. Garnett, M.J.; Edelman, E.J.; Heidorn, S.J.; Greenman, C.D.; Dastur, A.; Lau, K.W.; Greninger, P.; 
Thompson, I.R.; Luo, X.; Soares, J.; et al. Systematic identification of genomic markers of drug sensitivity 
in cancer cells. Nature 2012, 483, 570–575. 
31. Nakahara, T.; Kita, A.; Yamanaka, K.; Mori, M.; Amino, N.; Takeuchi, M.; Tominaga, F.; Kinoyama, I.; 
Matsuhisa, A.; Kudou, M.; et al. Broad spectrum and potent antitumor activities of YM155, a novel small-
molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer 
Sci. 2011, 102, 614–621. 
32. Ghadimi, M.P.; Young, E.D.; Belousov, R.; Zhang, Y.; Lopez, G.; Lusby, K.; Kivlin, C.; Demicco, E.G.; 
Creighton, C.J.; Lazar, A.J.; et al. Survivin is a viable target for the treatment of malignant peripheral nerve 
sheath tumors. Clin. Cancer Res. 2012, 18, 2545–2557. 
33. Xia, H.; Chen, J.; Shi, M.; Deivasigamani, A.; Ooi, L.L.; Hui, K.M. The over-expression of survivin enhances 
the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma. Oncotarget 2015, 6, 5990–6000. 
34. Sim, M.Y.; Huynh, H.; Go, M.L.; Yuen, J.S.P. Action of YM155 on clear cell renal cell carcinoma does not 
depend on survivin expression levels. PLoS ONE 2017, 12, e0178168. 
35. Winter, G.E.; Radic, B.; Mayor-Ruiz, C.; Blomen, V.A.; Trefzer, C.; Kandasamy, R.K.; Huber, K.V.M.; 
Gridling, M.; Chen, D.; Klampfl, T.; et al. The solute carrier SLC35F2 enables YM155-mediated DNA 
damage toxicity. Nat. Chem. Biol. 2014, 10, 768–773. 
36. Chang, B.H.; Johnson, K.; LaTocha, D.; Rowley, J.S.; Bryant, J.; Burke, R.; Smith, R.L.; Loriaux, M.; Müschen, 
M.; Mullighan, C.; et al. YM155 potently kills acute lymphoblastic leukemia cells through activation of the 
DNA damage pathway. J. Hematol. Oncol. 2015, 8, 39. 
37. Benjamin, Y.; Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to 
multiple testing. J. R. Stat. Soc. B. 1995, 57, 289–300. 
38. Kotchetkov, R.; Driever, P.H.; Cinatl, J.; Michaelis, M.; Karaskova, J.; Blaheta, R.; Squire, J.A.; Von Deimling, 
A.; Moog, J.; Cinatl, J. Jr. Increased malignant behavior in neuroblastoma cells with acquired multi-drug 
resistance does not depend on P-gp expression. Int. J. Oncol. 2005, 27, 1029–1037. 
39. Michaelis, M.; Rothweiler, F.; Barth, S.; Cinatl, J.; van Rikxoort, M.; Löschmann, N.; Voges, Y.; Breitling, R.; 
von Deimling, A.; Rödel, F.; et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor 
nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2011, 2, 
e243. 
40. Li, H.; Handsaker, B.; Wysoker, A.; Fennell, T.; Ruan, J.; Homer, N.; Marth, G.; Abecasis, G.; Durbin, R.; 
1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. 
Bioinformatics 2009, 25, 2078–2079. 
41. Koboldt, D.C.; Zhang, Q.; Larson, D.E.; Shen, D.; McLellan, M.D.; Lin, L.; Miller, C.A.; Mardis, E.R.; Ding, 
L.; Wilson, R.K. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome 
sequencing. Genome Res. 2012, 22, 568–576. 
42. Rees, M.G.; Seashore-Ludlow, B.; Cheah, J.H.; Adams, D.J.; Price, E.V.; Gill, S.; Javaid, S.; Coletti, M.E.; 
Jones, V.L.; Bodycombe, N.E.; et al. Correlating chemical sensitivity and basal gene expression reveals 
mechanism of action. Nat. Chem. Biol. 2016, 12, 109–116. 
43. Yang, W.; Soares, J.; Greninger, P.; Edelman, E.J.; Lightfoot, H.; Forbes, S.; Bindal, N.; Beare, D.; Smith, J.A.; 
Thompson, I.R.; et al. Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic 
biomarker discovery in cancer cells. Nucleic Acids Res. 2013, 41, D955–D961. 
44. Iorio, F.; Knijnenburg, T.A.; Vis, D.J.; Bignell, G.R.; Menden, M.P.; Schubert, M.; Aben, N.; Gonçalves, E.; 
Barthorpe, S.; Lightfoot, H.; et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell 2016, 166, 
740–754. 
45. Wickham, H. ggplot2: Elegant Graphics for Data Analysis; Springer: Berlin/Heidelberg, Germany, 2009. 
Cancers 2020, 12, 1080 17 of 17 
 
46. Mann, H.B.; Whitney, D.R. On a Test of Whether one of Two Random Variables is Stochastically Larger 
than the Other. Ann. Math. Stat. 1947, 18, 50–60. 
47. Pearson, K. Notes on regression and inheritance in the case of two parents. Proc. R. Soc. Lond. 1895, 58, 240–
242. 
 
 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution (CC 
BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
